Insulet Corporation: Beat — EPS $1.99, Revenue $842M
Earnings BeatQ3 2026 · Pre-market
Did Insulet Corporation (PODD) beat earnings today?
Yes, Insulet Corporation (PODD) beat Wall Street analyst expectations for Q3 2026, reporting higher-than-expected EPS and higher-than-expected revenue.
Earnings Per Share+25.16% surprise
$1.99Actual
Expected: $1.59
vs. year ago +59.9%
Total Revenue+1.12% surprise
$842MActual
Expected: $832.64M
vs. year ago +19.2%
Released Nov 04 · 7:00 AM ET
Earning Report
| Metric | Q3 2026 | Q3 2025 | YoY Change % |
|---|---|---|---|
| Revenue | $842.00M | $706.30M | 19.2 |
| Revenue detail — reported lines | |||
| └─U.S. Omnipod | $570.40M | $497.10M | 14.7 |
| └─International Omnipod | $266.20M | $202.10M | 31.7 |
| └─Total Omnipod | $836.60M | $699.20M | 19.7 |
| └─Drug Delivery | $5.50M | $7.10M | -22.7 |
| Net Income | $141.10M | $87.60M | 61.1 |
| GAAP Basic EPS | $2.03 | $1.24 | 63.7 |
| GAAP Diluted EPS | $2.03 | $1.24 | 63.7 |
| Adjusted EPS | $1.99 | $1.24 | 59.9 |
Financial Outlook / Guidance
| Metric | FY 2026 Guidance | |
|---|---|---|
| Guidance | Expected | |
| U.S. Omnipod | 17.5% - 18.5% (prev. 17% - 19% | — |
| International Omnipod | 32% - 33% (prev. 30% - 32% | — |
| Total Omnipod | 21.5% - 22.5% (prev. 21% - 23% | — |
| Drug Delivery | ~(40%) (prev. ~(40%) | — |
| Total | 21% - 22% (prev. 20% - 22% | — |
| Adjusted Operating Margin | ~150 bps YoY expansion (prev. ~100 bps YoY expansion | — |
| Adjusted EPS Growth | >30% (prev. >30% | $6.51 |
FY 2026 Guidance
- U.S. Omnipod
- Guidance17.5% - 18.5%(prev. 17% - 19%Expected—
- International Omnipod
- Guidance32% - 33%(prev. 30% - 32%Expected—
- Total Omnipod
- Guidance21.5% - 22.5%(prev. 21% - 23%Expected—
- Drug Delivery
- Guidance~(40%)(prev. ~(40%)Expected—
- Total
- Guidance21% - 22%(prev. 20% - 22%Expected—
- Adjusted Operating Margin
- Guidance~150 bps YoY expansion(prev. ~100 bps YoY expansionExpected—
- Adjusted EPS Growth
- Guidance>30%(prev. >30%Expected$6.51
Business Highlights
- ➤Completed U.S. sales force expansion and advanced the Type 2 action plan.
- ➤Completed full U.S. market release of Omnipod Discover.
- ➤Omnipod Discover reached more than 35,000 users and 5,000 healthcare professionals.
- ➤Extended the Omnipod 5 algorithm enhancement to full U.S. retail.
- ➤Expanded FreeStyle Libre 3 Plus integration across 10 international markets.
- ➤Presented global clinical evidence at EASD 2026.
- ➤Presented multinational Omnipod 5 real-world data from over 384,000 people across 17 countries.
- ➤EVOLUTION 3 demonstrated fully closed-loop benefits for adults with type 2 diabetes.
- ➤Completed enrollment in STRIVE2 and the EVOLVE pivotal study.
- ➤Board approved a $1 billion share repurchase program.
- ➤Expected approximately $400 million of fourth-quarter repurchases using existing cash.
Management Commentary
Ashley McEvoy, President and CEO
“Our team delivered a strong quarter, with revenue growth of nearly 20% and significant margin expansion. We are making continued progress on our type 2 action plan, strengthening our commercial capabilities, expanding our customer base, increasing manufacturing scale and advancing innovation. As we look ahead, the business is well positioned for durable, profitable growth. The share repurchase we are announcing today demonstrates our confidence in the strength of the Omnipod platform and Insulet's long-term trajectory.”